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Objective: To use deep sequencing to identify novel microRNAs (miRNAs) in human osteoarthritic
cartilage which have a functional role in chondrocyte phenotype or function.
Design: A small RNA library was prepared from human osteoarthritic primary chondrocytes using in-
house adaptors and analysed by Illumina sequencing. Novel candidate miRNAs were validated by
northern blot and qRT-PCR. Expression was measured in cartilage models. Targets of novel candi-
dates were identiﬁed by microarray and computational analysis, validated using 30-UTR-luciferase
reporter plasmids. Protein levels were assessed by western blot and functional analysis by cell
adhesion.
Results: We identiﬁed 990 known miRNAs and 1621 potential novel miRNAs in human osteoarthritic
chondrocytes, 60 of the latter were expressed in all samples assayed. MicroRNA-140-3p was the most
highly expressed microRNA in osteoarthritic cartilage. Sixteen novel candidate miRNAs were analysed
further, of which six remained after northern blot analysis. Three novel miRNAs were regulated across
models of chondrogenesis, chondrocyte differentiation or cartilage injury. One sequence (novel #11),
annotated in rodents as microRNA-3085-3p, was preferentially expressed in cartilage, dependent on
chondrocyte differentiation and, in man, is located in an intron of the cartilage-expressed gene CRTAC-1.
This microRNA was shown to target the ITGA5 gene directly (which encodes integrin alpha5) and
inhibited adhesion to ﬁbronectin (dependent on alpha5beta1 integrin).
Conclusion: Deep sequencing has uncovered many potential microRNA candidates expressed in human
cartilage. At least three of these show potential functional interest in cartilage homeostasis and osteo-
arthritis (OA). Particularly, novel #11 (microRNA-3085-3p) which has been identiﬁed for the ﬁrst time in
man.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Osteoarthritis (OA) is a degenerative joint disease characterised
by degradation of articular cartilage as well as thickening of sub-
chondral bone and formation of osteophytes at the joint margin1.
The chondrocyte is the only cell in cartilage, is crucial to tissueto: I.M. Clark, Biomedical
h Research Park, University of
3-592760; Fax: 44-(0)-1603-
r Ltd and Osteoarthritis Research Sfunction2 and must express appropriate genes to achieve tissue
homeostasis; this is altered in OA3.
Small non-coding RNAs, microRNAs (miRNAs), are important
regulators of gene expression in human cells. miRNAs are tran-
scribed as primary transcripts and processed to short stem-loop
structures (pre-miRNA) in the nucleus. The pre-miRNA is pro-
cessed by Dicer, forming two complementary short RNA molecules
one of which (the guide strand) is integrated into the RNA-induced
silencing complex (RISC), the other of which (the passenger strand
or miRNA*) is degraded4. After integration into RISC, miRNAs base
pair with their mRNA targets, usually in the 30UTR, but sometimes
in promoter or coding regions. Depending on the level of sequenceociety International. This is an open access article under the CC BY-NC-ND license
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cleaves the target mRNA (if complementarity is high) or suppresses
translation and mainly promotes more rapid mRNA degradation (if
complementarity is lower) the latter being predominant in
animals5,6.
Many miRNAs are regulated during cartilage development,
including by the cartilage-specifying transcription factor Sox9 (e.g.,
miR-140 and miR-455) (7,8, Barter et al., unpublished), or regulating
Sox9 expression (e.g., miR-675 and miR-145)9,10. Many miRNAs are
expressed differentially during OA11, though with high variability.
These include miR-9, miR-98, miR-146a12,13, miR-483, miR-149,
miR-582, miR-1227, miR-634, miR-576, miR-64114 andmiR-27a and
b15, though miRNA-140 is the most studied to date. MicroRNA-140
null mice are predisposed to the development of age-related OA-
like changes16,17 and increased cartilage destruction in surgically-
induced OA. Conversely, in an antigen-induced arthritis model,
transgenic over-expression of miR-140 in chondrocytes protected
against cartilage damage16.
There are 1881 precursors and 2588 mature human miRNAs in
Release 21 of miRBase (http://www.mirbase.org). Deep sequencing
has been used to identify potential newmiRNAs in a number of cells
and tissues, including rat cartilage during development18, however,
this has not been applied to human chondrocytes to date. In this
study, we aimed to use deep sequencing to identify novel miRNAs in
human osteoarthritic cartilage and identify their possible functional
roles. Osteoarthritic cartilage was used to reveal the maximum
number of disease-associated miRNAs. We sequenced libraries of
small RNAs puriﬁed from human osteoarthritic chondrocytes using a
recently developed approach19. Potential novel miRNAs were then
validated and characterised further. Of these, miRNA-3085, previ-
ously annotated in the mouse and rat, was identiﬁed as a human
miRNA, selectively expressed in cartilage, which affects chondrocyte
function via decreased expression of integrin alpha5.
Method
Cell culture
SW1353 chondrosarcoma cells were from American Type Cul-
ture Collection8. Primary human articular chondrocytes (HACs)
were isolated from osteoarthritic cartilage20. DF1 cells (a gift from
Prof. Andrea Münsterberg, University of East Anglia, UK) are
spontaneously transformed chicken ﬁbroblasts21. Parental and
DLD-1 Dicer null cell lines were from Horizon Discovery (Cam-
bridge UK) and originated from a colorectal adenocarcinoma.
Tissue collection
Femoral head and knee cartilage were obtained from OA [HOA
(Hip OA) age 61e89 years, 3M, 3F; KOA (Knee OA) age 55e71, 2F,
3M] and trauma [NOF (neck of femur), age 71e92 years, 3F, 3M]
patients undergoing total joint replacement surgery at the Norfolk
and Norwich University Hospital, UK. OA was diagnosed using
clinical history, examination and X-ray; conﬁrmation of gross pa-
thology wasmade at time of joint removal. Fracture patients had no
known history of joint disease and cartilagewas free of lesions. This
study was performed with Ethical Committee approval and all
patients provided informed consent. Cartilage was dissected and
snap frozen in liquid nitrogen within 30 min of surgery.
RNA puriﬁcation and quantitative real time PCR (qRT-PCR)
RNAwas puriﬁed from cartilage or HACs usingmirVana™miRNA
Isolation Kit (Life Technologies). For mRNA analysis by qRT-PCR
from cultured cells, cDNA synthesis used the ‘Cells-to-cDNA’method as described20. For direct reverse transcription from puri-
ﬁed RNA, Superscript II and qRT-PCR for mRNA expression was
performed as described8. Primer sequences are listed in
Supplementary Table 1. Primers to measure novel miRNAs were
designed using the Exiqon web-based assay tool, sequences for
these and primers for known miRNAs are proprietary.
Northern blot
RNA was separated on a 12% (w/v) polyacrylamide gel and
transferred to Hybond-NX membrane (Amersham Biosciences).
The blot was hybridised in ULTRAHyb-Oligo buffer (Life Technolo-
gies) with a gATP-labelled probe complementary to the miRNA at
37C overnight. Membranes were exposed to a Kodak Phosphor
Screen SD230 and scanned on a Molecular Imager FX reader (Bio-
Rad) for quantiﬁcation.
Next generation sequencing
Total RNA was extracted from primary HACs and small RNAs
enriched from 10 mg total RNA using the mirVana™miRNA Isolation
Kit. The small RNA library was prepared using the Illumina Small
RNA V1.5 Sample Preparation Guide, however sRNA adaptors were
substituted with High Deﬁnition (HD) adaptors19. Approximately
200 ng RNA enriched for small RNAwas ligated to adenylated 30 HD
adaptor with truncated T4 RNA ligase 2 (New England Biolabs). The
ligated fragment was then ligated to 50 HD adaptor using T4 RNA
ligase 1 (New England Biolabs). The ligated fragment was reverse
transcribed followed by PCR ampliﬁcation and size fractionated on
an 8% (w/v) PAGE gel. A band corresponding to 145e150bp was gel
puriﬁed and analysed on an Illumina Genome Analyzer IIX with
50 nt read length (Baseclear, Netherlands). Reads were trimmed for
4 nt barcodes on both ends and for Illumina adaptors on the 30 end.
Resulting reads longer than 16 nt were mapped to the human
genome (version GRCh38) using Patman software22, no mis-
matches were allowed. Reads mapping to more than 100 loci were
discarded. The remaining reads were inputted to miRCat23 with
default parameters. miRCat novel miRNA candidates were sepa-
rated from known miRNAs using in-house scripts.
Transfection with siRNA
Primary HACs were plated at 2.5  105 cells/well of a 6-well
tissue culture plate and incubated overnight in complete me-
dium. Cells were transfected in serum- and antibiotic-free DMEM
using Lipofectamine 2000 (Invitrogen), miRNA mimics at 30 nM
(Qiagen), miRNA inhibitors at 50 nM (Qiagen), or non-targetting
controls (All Stars at 30 nM (Qiagen), miScript Inhibitor control at
50 nM (Qiagen)), or mock transfection. Cells were incubated for 6 h
in serum-free and antibiotic-free media. Media was replaced with
complete medium for a further 48 h.
For functional analysis, RNA (pooled from three samples per
condition) was subjected towhole genome array using the Illumina
Human HT12v4 platform (Source Bioscience). Whole genome array
was normalised using R with the Lumi package24, background
correction and normalisation used a between-array quantile
methodology. Normalised data were analysed to measure fold-
change expression. Target sequences for novel candidate miRNAs
were identiﬁed using R with the Biostrings 2.28.0 package in
30UTRs of the human genome.
Chondrogenic differentiation
Human mesenchymal stem cells (hMSC) were resuspended in
chondrogenic culture medium consisting of high glucose
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pyruvate (Lonza), 10 ng/ml TGF-b3 (Peprotech), 100 nM dexa-
methasone, 1 ITS-1 premix, 40 mg/ml proline, and 25 mg/ml
ascorbate-2-phosphate (all from SigmaeAldrich, Poole, UK).
5  105 hMSC in 100 ml medium were pipetted onto 6.5 mm
diameter, 0.4-mm pore size polycarbonate Transwell ﬁlters (Merck
Millipore), centrifuged in a 24-well plate (200 g, 5 min), then 0.5 ml
of chondrogenic medium was added to the lower well as
described25. Media were replaced every 2 or 3 days up to 14 days.
Mouse femoral head cartilage wounding assay
A mouse femoral head cartilage wounding assay was as previ-
ously described26. Brieﬂy, the acetabulofemoral joint was exposed,
the hip joint dislocated and the femoral cap was avulsed using
forceps. Tissue was cultured in serum-free medium and harvested
into 500 ml Trizol (Life Technologies) at the time points: 0, 1, 3, 6, 12,
24 and 48 h and stored at 80C. Samples were homogenized with
a disposable pestle, insoluble material removed by centrifugation
and RNA puriﬁed as manufacturer's instructions.
Transient transfection
The 30 UTR of mRNAs was ampliﬁed by PCR (using primers in
Supplementary Table 1) and subcloned into the pmirGLO Dual-
Luciferase Vector (Promega). Mutation of the miRNA seed
sequence used QuikChange (Agilent). Constructs were sequence
veriﬁed. DF1 cells were plated into a 96 well plate at
3.75  104 cells/cm2 overnight, transfected with 100 ng luciferase
reporter plasmid, 50 nM miRNA mimic, inhibitor or control using
Lipofectamine 2000 according to manufacturer's instructions
(Invitrogen), and incubated for 48 h. Cell lysates were assayed using
the Dual Luciferase Reporter Assay Kit (Promega) and luciferase
was normalised to renilla to control for the transfection efﬁciency.
Western blot
Whole cell lysates were harvested into ice cold RIPA buffer
(50 mM Tris-HCL pH7.6, 150 mM NaCl, 1% (v/v) Triton x-100, 1% (w/
v) sodium deoxycholate, 0.1% (w/v) SDS, 10 mMNaF, 2 mMNa3VO4,
1x protease cocktail III tablet (Fisher Scientiﬁc)). Samples were
separated on reducing SDS-PAGE, transferred to PVDF membrane
and probed overnight at 4C. The anti-integrin alpha5 antibody
(Abcam ab150361) was detected using HRP-conjugated secondary
antibodies (DAKO), visualised using LumiGLO reagent (New En-
gland Biolabs) and exposed to Kodak Biomax MS ﬁlm
(SigmaeAldrich).
Cell adhesion
96-well plates were coated overnight with 10 mg/ml ﬁbronectin
(SigmaeAldrich) at 4C and blocked with 1% (w/v) BSA. SW1353
cells were transfected with 100 nM miRNA mimic, siRNA against
ITGA5 or All Stars non-targetting control for 48 h as above. Cells
were trypsinised and resuspended in serum-free medium atFig. 1. Gene expression in articular chondrocyte isolation and expansion. Expression levels
RNA isolated from: osteoarthritic knee cartilage tissue, isolated chondrocytes (post digest) a
were normalised to 18S rRNA (mRNA) or U6 RNA (miRNA) expression. (RNAwas obtained fro
post hoc Tukey test was used to test for signiﬁcance; data are plotted as mean ± 95% conﬁden
showed 630 known miRNA in all three samples sequenced, the 20 miRNA with the highest r
Expression of candidate novel miRNA #7 and #8 was measured by northern blot using 10 m
was used as a size control and the small RNA U6 was used as a standard reference for the4  105 cells/ml. Antibodies (anti-alpha5 integrin, Abcam ab25251
or control IgG) were added to cell suspension at 10 mg/ml and pre-
incubated for 10 min at 37C. Cells were added at 100 ml per well in
at least triplicate for 15 min. Cells were ﬁxed with 4% (v/v) para-
formaldehyde and stained with 1% (w/v) methylene blue in 10 mM
sodium borate. Cells were lysed with 50% (v/v) ethanol in 0.1M HCl
for 15 min and absorbance measured at 590 nm.
Statistics
Data are plotted as mean with 95% conﬁdence intervals. Data
were tested for normality prior to further analysis using Student's t-
test to compare between two samples, or one-way ANOVA with
post-hoc Tukey's test to compare between multiple samples. All
statistical analyses were performed using GraphPad Prism version
5 or PASW Statistics 18.
Results
Puriﬁcation of RNA
We sought to identify optimal samples for sequencing to detect
all cartilage miRNAs. Total RNA was puriﬁed from articular carti-
lage taken at total knee replacement for OA, chondrocytes
immediately after tissue digestion and cells across passage in
monolayer culture. Fig. 1(A) shows that COL2A1 expression
decreased and COL1A1 increased with chondrocyte isolation and
culture as expected. MicroRNA-140-5p increased in expression
(~2-fold, p ¼ 0.0005) in chondrocytes digested from cartilage
[Fig. 1(B)], then decreased in monolayer. Interestingly, miR-140-3p
was highest in cartilage and then decreased across isolation and
passage [Fig. 1(B)]. Since miR-140-5p is strongly implicated in OA,
we used RNA isolated from cells digested from cartilage (which
also gives the highest quality RNA) as the starting point for
sequencing studies.
Small RNA high-throughput sequencing
cDNA libraries were generated from small RNA isolated from
chondrocytes taken from three independent osteoarthritic knees.
High deﬁnition adaptors were used (see Methods) to reduce bias
and reveal maximum sequence19. Approximately 20 million
sequencing reads were obtained per sample and analysed using
miRCat23. Known miRNAs were conﬁrmed using miRBase (Release
20, www.mirbase.org/27) with 990 individual known miRNAs
within the dataset, of which 630 were present in all three patients.
The 20miRNAs with highest read number per 107 sequencing reads
are shown in Fig. 1(C). Surprisingly, the greatest number of
sequencing reads came from miR-140-3p, the so-called passenger
strand of miR-140 and investigation of its function is the subject to
another manuscript (Wheeler et al. in preparation). Most of the top
20 miRNAs have previously been linked with cartilage or arthritis,
apart from miR-23a, miR-100 and miR-99a11.
MiRCat generated 60 candidate novel miRNAs in all three
samples (Supplementary Table 2). These 60 candidates wereof (A) COL2A, COL1A1, (B) miR-140-5p, miR-140-3p were measured by qRT-PCR from
nd subsequent P0, P1, P2, and P3 passaged chondrocytes from monolayer culture. Data
m 8 patients for chondrocytes and 4 patients for tissue; a one way Anova analysis with a
ce interval. (C) Deep sequencing of a small RNA library of post-digest chondrocyte RNA
ead numbers are shown; n ¼ 3, data are plotted as mean ± 95% conﬁdence interval. (D)
g SW1353 total (T) RNA or 2 mg of RNA enriched (E) for small RNAs. MicroRNA-140-3p
northern blot.
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ber of genomic locations; read number; level in Dicer 1 null cells),
reducing the number of candidate miRNAs to 16.
Measurement of candidate miRNAs
Initially, candidate miRNAs were measured by northern blot in
total RNA puriﬁed from SW1353 chondrosarcoma cells. A number
of novel candidates gave bands at high molecular weight, larger
than miRNAs (data not shown; novel #1, #3, #4, #5, #9, #12, #13,
#15, #16). Novel #7 and #8 gave an appropriately sized band
similar to miR-140-3p [Fig. 1(D)]. Novel #6 gave multiple small
bands. Novel #2, #10, #11 and #14 gave no signal (data not shown)
and were included in further analyses.
Incorrect size on northern therefore triaged 10 miRNAs. The six
remaining candidate novel miRNAs, including those with no
detectable signal on northern blot, were measured by qRT-PCR in
hip cartilage from OA patients and patients fracturing their neck of
femur (NOF) [novel #2, #7 and #11, miR-140 andmiR-455 shown in
Fig. 2(A)e(D)]. No candidate novel miRNAs showed a signiﬁcant
difference between hip OA cartilage compared to NOF. MicroRNA-
140-5p showed a trend to increased expression (p ¼ 0.0587) in
OA cartilage compared to NOF as we have previously reported8; the
more highly expressed miR-140-3p showed no difference between
groups.Fig. 2. MicroRNA expression in cartilage tissue from hip osteoarthritis (HOA) and hip cartila
455, (B) candidate novel miRNA #2, (C) candidate novel miRNA #7, (D) candidate novel miR
normalised to U6 RNA expression. Graphs show mean ± 95% conﬁdence interval. n ¼ 6, anDuring the course of this project, a number of our novel miRNAs
were annotated on miRBase. Novel #2, hsa-miR-6509-5p; #7, hsa-
miR-664b-3p; #8 is a truncated form of hsa-miR-1277-5p; #10,
hsa-miR-487a-5p; #11, mmu/rno-miR-3085-3p (though not an-
notated as a human miRNA). Since none of these have been further
characterised, they remained in downstream analyses.
All novel miRNAs were measured in articular cartilage and
across human tissue panels. Novel #11 showed selectivity of
expression in cartilage compared to any other tissue [Fig. 3(A)]. This
was equivalent to miRNA-140-5p [Fig. 3(B)] or miR-140-3p (data
not shown) and similar to miRNA-455-3p or miR-455-5p [Fig. 3(C)]
though this miRNA showed strong expression in cervix. Expression
patterns of the other candidates were widespread and not pre-
dominant in cartilage (data not shown).
Further characterisation of candidate miRNAs
Three miRNAs, novel #2, #7 and #11, were all expressed at a
statistically signiﬁcantly lower level in a Dicer null cell line (DLD-1)
than in an isogenic wild type control line (data not shown), and
these were analysed further.
Fig. 4(A) shows that novels #7 and #11 have signiﬁcantly higher
expression in cartilage tissue than extracted cells, with further
decrease in monolayer or with increasing passage. Novel #2 is not
modulated by cell extraction or culture (data not shown).ge following fracture to the neck of femur (NOF). Expression levels of (A) miR-140, miR-
NA #11 were obtained by qRT-PCR from RNA isolated from cartilage tissue. Data were
alysed by Student's t-test.
Fig. 3. MicroRNA expression across a human tissue panel. Expression levels of miRNAs
(A) candidate novel miRNA #11, (B) miRNA-140-5p, (C) miRNA-455-5p were obtained
by qRT-PCR from RNA isolated from 23 human tissues as shown. NOF, hip cartilage
following fracture to the neck of femur; HOA, hip osteoarthritis; KOA, knee osteoar-
thritis. Data were normalised to U6 RNA expression. RNA of all cartilage samples was
from 3 patients. RNA from all remaining tissues was from a pool of three patients with
n ¼ 3 technical replicates. Data are plotted as mean ± 95% conﬁdence interval.
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derived MSC, expression of novel #2 increased at day 7, but
decreased to later time points [Fig. 4(B)], similarly to Sox925. Novel
#7 increased throughout cartilage formation [Fig. 4(B)], more
similarly to COL2A125. Novel #11 showed no signiﬁcant change
across the 14 days (data not shown).
In the mouse hip avulsion assay of cartilage wounding, novel #7
increased in expression across 48 h, whilst candidate #11 was
expressed in a biphasic pattern, with two peaks across 48 h
[Fig. 4(C)]. Novel #2 is not found in the mouse genome. MicroRNA-
140 (both strands) and miR-455 (both strands) increased in
expression across the time course similarly to novel #7 (data not
shown).ITGA5 is a direct target of novel #11 (miR-3085-3p)
Primary HACs (from three separate patients) were transfected
with either miRNA mimics or inhibitors for novels #2, #7 and #11
or negative controls for 48 h, followed by microarray. Genes which
are true targets of the miRNA will decrease in expression in cells
treated with miRNA mimics, increase in expression in cells treated
with miRNA inhibitors and contain a seed sequence for the miRNA
in their 30UTR. Supplementary Table 3(A)-(C) show the top genes
for each candidate which ﬁt these criteria.
Since novel #11 was expressed in a cartilage-selective manner,
and qRT-PCR veriﬁed ITGA5 as a potential target (data not shown),
this gene was further assessed. Fig. 5(A) shows that expression of
luciferase controlled by the 30UTR of ITGA5was decreased by novel
#11 and that this effect was abrogated bymutation of the seed sites
(from AGCCAG to GAGCTC). This demonstrates that novel #11
directly targets the ITGA5 gene.Western blot shows that the level of
integrin alpha5 (encoded by ITGA5) is reduced by transfection with
the novel #11 miRNA mimic [Fig. 5(B)], with the same bands
reduced by an ITGA5 targeting siRNA. The functional potential of
novel #11 was probed by measuring adhesion to ﬁbronectin,
mediated by integrin alpha5beta1. A function blocking antibody
against integrin alpha5 reduces adhesion, as does EDTA. Trans-
fection of cells with candidate #11 inhibited adhesion to a similar
extent to siITGA5 [Fig. 5(C)].
Discussion
We initially sought to identify the best source of chondrocyte
RNA from which to identify miRNAs. We measured a number of
miRNA and mRNA known to be important in OA across cartilage
tissue and cells derived from it across passage in culture. For
miRNA-140-5p, the miRNA most implicated in cartilage homeo-
stasis and OA, expression was highest in cells digested from carti-
lage rather than in the tissue itself. This increased expression of
miR-140-5p may be a response to injury, a known phenomenon
for miRNAs in several areas of physiology and pathology, including
cartilage e.g.,28,29. Expression of both MMP1 and MMP13 is also
signiﬁcantly higher in cells digested from cartilage compared to the
tissue itself (data not shown).
We sequenced libraries from three OA patients using so-called
‘high deﬁnition’ adaptors19 which have been shown to approxi-
mately double read coverage, ﬁnding 60 potential new miRNA se-
quences in all three. Sun et al. undertook a deep sequencing
analysis of rat cartilage across development and uncovered 86
novel candidate miRNAs18, however, further validation of these
sequences was not reported.
The miRCat software23 was used to designate miRNAs by
factors including, location, abundance, secondary structure,
number of mismatches between 5p and 3p strand and hairpin
length. These sequences were then searched in miRBase27 to
discount miRNAs already known and novel sequences further
triaged as described. This led to 16 potential novel miRNAs being
further investigated. New releases of miRBase have included
some of the candidate novel miRNAs, identiﬁed in other
sequencing projects.
The levels of each miRNA using either deep sequencing, north-
ern blot, or qRT-PCR were not comparable. It has previously been
reported that measurement between platforms shows high vari-
ability30. miRNAs vastly different in read number within the
sequencing library, where bias is known, showed much closer
expression in northern blot analysis (e.g., miR-140, miR-455 and
novel #7 or #8) or in qRT-PCR (e.g., mean Ct for miR-455-5p in hip
OA cartilage ¼ 25.11 and for novel #11 ¼ 28.2), where Ct < 30 is
robust expression.
Fig. 4. MicroRNA expression in models of chondrocyte differentiation or injury. (A) MicroRNA expression in articular chondrocyte isolation and expansion. Expression levels of
candidate miRNA novel #7 and novel #11 were measured by qRT-PCR from RNA isolated from: osteoarthritic knee cartilage tissue, isolated chondrocytes (post digest) and sub-
sequent P0, P1, P2, and P3 chondrocytes passaged through monolayer culture. Data were normalised to U6 RNA expression. (RNAwas obtained from 8 patients for chondrocytes and
4 patients for tissue; a one way Anova analysis with a post hoc Tukey test was used to test for signiﬁcance; data are plotted as mean ± 95% conﬁdence interval.). (B) MicroRNA
expression in a mesenchymal stem cell chondrogenesis assay. Expression levels of candidate miRNA novel #2 and novel #7 were measured by qRT-PCR from RNA obtained from
mesenchymal stem cells induced through chondrogenesis to form cartilage discs. RNA samples were taken at time points during the assay: day 0, 3, 7, 14. Data shows mean ± 95%
conﬁdence interval, n ¼ 3, data were normalised to U6 RNA expression and analysed by a one way ANOVA with a post hoc Tukey test. (C) MicroRNA expression in a cartilage injury
model. Expression levels of candidate miRNA novel #7 and novel #11 were obtained by qRT-PCR from RNA isolated from hip cartilage removed from 3 to 5 week old mice and
incubated in culture medium for 48 h. RNAwas isolated at the time points; 0, 1, 3, 6, 12, 24 and 48 h. Data shows mean ± 95% conﬁdence interval, n ¼ 8. Data were normalised to U6
RNA expression and analysed by a one way ANOVA with a post hoc Tukey test.
N. Crowe et al. / Osteoarthritis and Cartilage 24 (2016) 534e543540Northern blot showed that two candidate novel miRNAs, #7 and
#8 gave an appropriately sized band and can be assigned as miR-
NAs; this conﬁrms recent sequence identiﬁcation for novel #7 as
miR-664b-3p and novel #8 as miR-1277-5p. Four candidate novel
miRNAs, #2, #10, #11 and #14, gave no signal, and may be more
weakly expressed in the SW1353 chondrosarcoma cell line used.Three of these have since been described as miRNAs in recent
versions of miRBASE (#2, #10 and #11). Ten candidate novel miR-
NAs were discounted on the basis of their size.
Expression across a broad tissue panel showed that only novel
miRNA #11 was selectivity expressed in articular cartilage. This
pattern was similar for miR-140, with miR-455 showing high
Fig. 5. Functional analysis of integrin alpha5 as a target of candidate microRNA #11. (A)
The schematic shows the ITGA5 cDNA with the location of target sites numbered. Cells
(DF1) were transfected with the 30UTR of ITGA5 cloned into pmiRGLO, or a construct
with either or both miR-3085-3p seed sites mutated (to GAGCTC) (mutant 1, 2 or
1 þ 2), with or without candidate miRNA #11 (miR-3085-3p) mimic or non-targeting
control. Fireﬂy luciferase relative light units were normalised to Renilla relative light
units. Data are mean ± 95% conﬁdence interval, n ¼ 6, analysed by a Student's t test. (B)
SW1353 cells had no treatment (control), mock transfected, or transfected with a miR-
3085 mimic, an siRNA against ITGA5 (siITGA5) or non-targeting siRNA; protein was
extracted and separated on 12.5% (w/v) SDS-PAGE, blotted onto PVDF and probed with
an anti-integrin alpha5 antibody. The blot was stripped and re-probed with a GAPDH
antibody to assess loading. (C) SW1353 cells were transfected with a miR-3085 mimic,
siITGA5 or a non-targeting control (100 nM) for 48 h. Cells were pre-incubated in
serum-free medium with an anti-integrin alpha5 antibody or control antibody (10 mg/
ml) or EDTA (2 mM) for 10 min if required and then allowed to adhere to ﬁbronectin
for 15 min. After washing cells were ﬁxed and stained with methylene blue, lysed and
absorbance at 590 nm measured. Data are normalised to the control and presented as
mean ± 95% conﬁdence interval, n ¼ 4e6, analysed by a Student's t test).
N. Crowe et al. / Osteoarthritis and Cartilage 24 (2016) 534e543 541expression in cervix as well as articular cartilage. Novel #11 is an-
notated in miRBase as miR-3085 but only in the mouse or rat. In
these species, the miRNA is 30 to cartilage acidic protein 1 (CRTAC1,
previously called CEP-68), however, in man, it is within a ﬁnal
intron of the gene, though these longer human transcripts have not
yet been annotated in rodents. The miRNA is conserved in mam-
mals (data not shown). Many intronic miRNAs are functionally
related to the genes they are within31. Cartilage acidic protein 1 is a
protein of unknown function, which was originally described as a
marker of chondrocytes in culture, able to delineate between MSC,
chondrocytes and osteoblast-like cells32. The gene is expressed in
both cartilage and bone tissue, but rapidly lost from osteoblasts
upon culture32. Its expression is also markedly decreased when
chondrocytes are digested from cartilage, but increased again in 3D
culture33. CRTAC1 is also reported to be increased in expression in
microarrays of human OA cartilage (e.g.,3,34). CRTAC-1 protein has
been identiﬁed in the plasma of patients with long-bone fracture,
where it was suggested either to indicate normal callus formation
and healing or concomitant joint injury35.
Novel miRNA #2 (not found in mouse) is located in an intron of
the gene WDR91 which has no known function, whilst novel #7
comes from the snoRNA SNORA36A. It has been shown that miRNAs
can be derived from snoRNAs36, and indeed miR-140 has been
described as snoRNA-like miRNA37.
The pattern of expression of each miRNA in a variety of cell
models was different. Broadly, novel miRNA #7 follows the same
pattern as miR-140-5p and miR-455-5p and -3p. Novel #11 de-
creases with chondrocyte dedifferentiation, but does not repro-
ducibly increase in the MSC chondrogenesis model.
We used overexpression of a miRNA mimic or inhibitor in pri-
mary HACs to deﬁne direct targets of the novel miRNAs. A number
of possible targets are identiﬁed bioinformatically, though these
remain to be validated in future studies. Several potential targets
have been implicated in cartilage and OA. For novel miRNA #2,
PDGF-D is a recently discovered platelet-derived growth factor
isoform, where PDGF has been shown to regulate chondrocyte
proliferation38; secreted frizzled-related protein 4 (sFRP4) is a Wnt
antagonist with the Wnt pathway key in cartilage homeostasis and
OA39; TGFBR3 encodes betaglycan, a co-receptor for TGFb, another
pathway key in OA40. For novel miRNA #7, cartilage intermediate
layer protein has been implicated in cartilage structure, but also in
calciﬁcation and can interact with key growth factor pathways (e.g.,
TGFb or IGF)41. Sox4 is a SoxC gene, shown to be involved in skel-
etogenesis, but also in Wnt signalling42. TIMP-3 is an inhibitor of
cartilage-degrading proteinases43. Versican, a cartilage proteogly-
can has been mooted as a biomarker, along with TIMP-3, in
shoulder OA44. For novel miRNA #11 (miR-3085-3p), IL-18 and
Myd88 are known to be involved in tissue inﬂammation45 and
TGFBR3 is also a predicted target for this miRNA as well as novel
miRNA #2 above.
The ITGA5 gene was shown to be a direct target of novel #11
(miR-3085-3p) and the miRNA strongly reduced the level of
integrin alpha5 protein in chondrocytes. Integrin alpha5beta1 has
been implicated in cartilage homeostasis and destruction46, e.g.,
mediating signalling through matrix fragments and mechano-
transduction. Functionally, novel #11 (miR-3085-3p) was shown to
inhibit chondrocyte binding to ﬁbronectin to the same extent as a
speciﬁc siRNA against ITGA5 [Fig. 5(C)]. Fibronectin is a glycopro-
tein found in the superﬁcial zone of cartilage and is increased in OA;
functionally is has a role in lubrication, matrix organisation and in
cartilage development47e50. The impact of novel #11 (miR-3085-
3p) on the reported ﬁbronectin fragment-induced expression of
MMP13 through alpha5beta1 was measured, but this miRNA also
reduces the expression of basalMMP13, even though this gene does
not have a seed sequence for this miRNA (data not shown). This
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expression decreases with the mimic and increases with the in-
hibitor of novel #11, potentially via the NFkB, STAT and retinoic acid
receptor pathways which are also targeted.
In summary, we have identiﬁed and validated several miRNA
candidates from human osteoarthritic cartilage. Most interestingly,
novel #11 is annotated in mouse and rat as miRNA-3085-3p, but is
30 of a cartilage expressed gene CRTAC1. In man, longer transcripts
of this gene have been annotated and it is located in the last intron
of the gene. This miRNA has high expression in cartilage which
decreases on chondrocyte dedifferentiation, is expressed in a
cartilage-selective manner and we have shown it to target the
ITGA5 gene directly, functionally disrupting integrin alpha5. These
data will allow the further functional characterisation of identiﬁed
miRNAs. It is clear that a number of miRNAs function in cartilage
and are dysregulated in OA. A detailed understanding of the role of
miRNAs in OA will allow their targeting to prevent or slow the
progression of the disease.
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